KD025: Phase II started

Kadmon began a double-blind, U.S. Phase II trial to evaluate oral KD025 for 16 weeks in about 150 patients. Patients will receive 200 mg KD025 once or twice daily; 400 mg KD025 once daily; 400 mg KD02...